Parenteral Drugs (India) (NSE:PDPL) Total Assets: ₹4,842.34 Mil (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Total Assets?

Parenteral Drugs (India) NSE:PDPL 4 Total Assets is ₹4,842.34 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Total Assets for the quarter that ended in Mar. 2022 was ₹4,842.34 Mil.

Total Assets is connected with ROA %. Parenteral Drugs (India)'s annualized ROA % for the quarter that ended in Mar. 2022 was 19.67%. Total Assets is also linked to Revenue through Asset Turnover. Parenteral Drugs (India)'s Asset Turnover for the quarter that ended in Mar. 2022 was 0.00.

Parenteral Drugs (India)  (NSE:PDPL) Total Assets Explanation

Total Assets is connected with ROA %.

Parenteral Drugs (India)'s annualized ROA % for the quarter that ended in Mar. 2022 is

ROA %=Net Income (Q: Mar. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Mar. 2022 ))/ count )
=952.516/( (0+4842.338)/ 1 )
=952.516/4842.338
=19.67 %

Note: The Net Income data used here is four times the quarterly (Mar. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Parenteral Drugs (India)'s Asset Turnover for the quarter that ended in Mar. 2022 is

Asset Turnover
=Revenue (Q: Mar. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Mar. 2022 ))/ count )
=17.731/( (0+4842.338)/ 1 )
=17.731/4842.338
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Parenteral Drugs (India) Total Assets Related Terms

Parenteral Drugs (India) Total Assets Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Total Assets Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,904.22 5,405.70 5,518.51 5,682.04 4,842.34

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,682.04 0.00 5,773.18 0.00 4,842.34
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Parenteral Drugs (India)'s Total Assets for the fiscal year that ended in Mar. 2022 is calculated as

Total Assets=Total Equity (A: Mar. 2022 )+Total Liabilities (A: Mar. 2022 )
=-8239.081+13081.419
=4,842.34

Parenteral Drugs (India)'s Total Assets for the quarter that ended in Mar. 2022 is calculated as

Total Assets=Total Equity (Q: Mar. 2022 )+Total Liabilities (Q: Mar. 2022 )
=-8239.081+13081.419
=4,842.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of ₹4,842.34 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Total Assets of ₹4,842.34 Mil as of Mar. 2022. The total amount of assets as recorded on a company's balance sheet. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Total Assets too high?
Parenteral Drugs (India)'s current Total Assets is ₹4,842.34 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Total Assets compare to ZTS and CTLT?
Parenteral Drugs (India)'s Total Assets of ₹4,842.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Total Assets is ₹4,842.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Total Assets of ₹4,842.34 Mil. The current Total Assets is ₹4,842.34 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Total Assets is ₹4,842.34 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price